此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Aspergillosis and Humoral Alveolar Immunity by Proteomics (ASPEOMIC)

2021年1月24日 更新者:Assistance Publique - Hôpitaux de Paris

Aspergillus fumigatus is the most common opportunistic mold found in lung fungal infections in humans. Aspergillus is the cause of invasive pulmonary aspergillosis with a poor prognosis in immunocompromised patients and the chronic pulmonary aspergillosis which affects 3 million patients worldwide, with underlying pulmonary pathologies such as tuberculosis and its sequelae. The medicinal means to fight against these different forms are limited and not very effective. In addition, the emergence of resistance makes the search for new therapeutic strategies of major importance.

The interaction between the fungal spore and our innate immune system is the first step leading to infection.

The innate immune system is made up of cellular immunity and humoral immunity. While the first is well described, the second, consisting of soluble mediators, is essential for anti-aspergillus immunity but relatively little studied. The study of soluble mediators present in the alveolar fluid interacting directly with the Aspergillus spore would make it possible to analyze the first stages of infection. The analysis of the proteome present in the bronchoalveolar lavage of uninfected patients, suffering from various forms of aspergillosis and suffering from other types of infections would make it possible to highlight the essential and specific components of anti- immunity aspergillary.

The objective of this study is to analyze the protein profiles of innate immunity in the pulmonary alveoli in the absence or presence of Aspergillus or non-fungal infection in order to highlight the soluble mediators of the more specific immunity of the Aspergillosis.

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (预期的)

32

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with or without pulmonary aspergillosis for whom a bronchial fibroscopy with bronchoalveolar lavage is performed as part of their care path.

描述

Inclusion Criteria for the case group (IPA / CPA): :

  1. Patient who are more than 18 years old
  2. Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of IPA or CPA in current care. Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019).
  3. Patient who has given his consent.

Inclusion Criteria In the control group :

  1. Patient who are more than 18 years old
  2. Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care. Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)
  3. Patient who has given his consent.

Exclusion Criteria for the case and the control group:

  1. Pregnant woman
  2. Patient deprived of their rights
  3. Patient under tutorship or guardianship or under the protection of a conservator

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:其他
  • 时间观点:预期

队列和干预

团体/队列
干预/治疗
Cases

Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of invasive pulmonary aspergillosis (IPA) or Chronic pulmonary aspergillosis (CPA) in current care :

  • Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019) or
  • Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)
Analysis of the protein content by proteomics of bronchoalveolar lavage
Control Group
Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care
Analysis of the protein content by proteomics of bronchoalveolar lavage

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Protein profile
大体时间:at day 90
Protein profiles of innate immunity in the pulmonary alveoli
at day 90

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年2月1日

初级完成 (预期的)

2021年4月1日

研究完成 (预期的)

2021年4月1日

研究注册日期

首次提交

2021年1月24日

首先提交符合 QC 标准的

2021年1月24日

首次发布 (实际的)

2021年1月28日

研究记录更新

最后更新发布 (实际的)

2021年1月28日

上次提交的符合 QC 标准的更新

2021年1月24日

最后验证

2021年1月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • APHP201003

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅